These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 18391605

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Combination therapy with VP16 and ethinylestradiol for hormone-refractory prostate cancer: good response with tolerability.
    Azuma H, Inamoto T, Takahara K, Ibuki N, Koyama K, Utimoto S, Fujisue Y, Uehara H, Komura K, Nomi H, Ubai T, Katsuoka Y.
    Anticancer Res; 2010 Sep; 30(9):3737-45. PubMed ID: 20944163
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
    Rago RP, Einstein A, Lush R, Beer TM, Ko YJ, Henner WD, Bubley G, Merica EA, Garg V, Ette E, Harding MW, Dalton WS.
    Cancer Chemother Pharmacol; 2003 Apr; 51(4):297-305. PubMed ID: 12721757
    [Abstract] [Full Text] [Related]

  • 6. Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up.
    Berruti A, Fara E, Tucci M, Tarabuzzi R, Mosca A, Terrone C, Gorzegno G, Fasolis G, Tampellini M, Porpiglia F, De Stefanis M, Fontana D, Bertetto O, Dogliotti L, Gruppo Onco-Urologico Piemontese, Rete Oncologica Piemontese.
    Urol Oncol; 2005 Apr; 23(1):1-7. PubMed ID: 15885575
    [Abstract] [Full Text] [Related]

  • 7. Oral estramustine and oral etoposide for hormone-refractory prostate cancer.
    Dimopoulos MA, Panopoulos C, Bamia C, Deliveliotis C, Alivizatos G, Pantazopoulos D, Constantinidis C, Kostakopoulos A, Kastriotis I, Zervas A, Aravantinos G, Dimopoulos C.
    Urology; 1997 Nov; 50(5):754-8. PubMed ID: 9372887
    [Abstract] [Full Text] [Related]

  • 8. Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.
    Meluch AA, Greco FA, Morrissey LH, Raefsky EL, Steis RG, Butts JA, Hainsworth JD, Minnie Pearl Cancer Research Network.
    Cancer; 2003 Nov 15; 98(10):2192-8. PubMed ID: 14601089
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.
    Hussain M, Tangen CM, Lara PN, Vaishampayan UN, Petrylak DP, Colevas AD, Sakr WA, Crawford ED, Southwest Oncology Group.
    J Clin Oncol; 2005 Dec 01; 23(34):8724-9. PubMed ID: 16314632
    [Abstract] [Full Text] [Related]

  • 11. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma.
    Hellerstedt B, Pienta KJ, Redman BG, Esper P, Dunn R, Fardig J, Olson K, Smith DC.
    Cancer; 2003 Oct 15; 98(8):1603-10. PubMed ID: 14534875
    [Abstract] [Full Text] [Related]

  • 12. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
    Pienta KJ, Smith DC.
    Semin Oncol; 1997 Oct 15; 24(5 Suppl 15):S15-72-S15-77. PubMed ID: 9346227
    [Abstract] [Full Text] [Related]

  • 13. Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer.
    Numata K, Miura N, Azuma K, Karashima T, Kasahara K, Nakatsuzi H, Hashine K, Sumiyoshi Y.
    Hinyokika Kiyo; 2007 Feb 15; 53(2):99-104. PubMed ID: 17352158
    [Abstract] [Full Text] [Related]

  • 14. Serum PSA half-life as a predictor of survival for hormone-refractory prostate cancer patients: modelization using a standardized set of response criteria.
    Banu E, Banu A, Medioni J, Levy E, Thiounn N, Mejean A, Andrieu JM, Oudard S.
    Prostate; 2007 Oct 01; 67(14):1543-9. PubMed ID: 17705243
    [Abstract] [Full Text] [Related]

  • 15. Phase II study of prolonged ambulatory infusion carboplatin and oral etoposide for patients progressing through hormonal therapy for prostate cancer.
    Olver I, Keefe D, Myers M.
    Intern Med J; 2005 Jul 01; 35(7):405-8. PubMed ID: 15958110
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
    James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, Dawson NA.
    Eur Urol; 2009 May 01; 55(5):1112-23. PubMed ID: 19042080
    [Abstract] [Full Text] [Related]

  • 20. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
    Amato RJ, Hernandez-McClain J, Henary H.
    Am J Clin Oncol; 2008 Dec 01; 31(6):532-8. PubMed ID: 19060583
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.